Table 1A.
Basic demographic data at baseline [count (percent) and mean (standard deviation), respectively] with respect to study groups.
| Rescue group | Intervention group | |
|---|---|---|
| N | 23 (49%) | 24 (51%) |
| Sex (female) | 9 (39%) | 9 (38%) |
| Age (years) | 56 (±16.5) | 58 (±12.8) |
| BMI (kg/m2) | 27.4 (±4.26) | 28.8 (±6.22) |
| eGFR (mL/min per 1.73 m2) | 27 (±9.7) | 25.33 (±7.5) |
| Serum (mmol/L) | 19.2 (±1.5) | 18.8 (±1.8) |
| Urine sodium (mmol/24 h) | 186 (±88) | 190 (±79) |
| Urine pH | 5.5 (±1.1) | 5.3 (±0.54) |
| Number of antihypertensives | 64 (2.8 per subject) | 48 (2.0 per subject) |
| Type of antihypertensive | ||
| Diuretics | 15 (65%) | 8 (33%) |
| Calcium antagonist | 11 (48%) | 10 (42%) |
| ACEi/ARB | 19 (83%) | 18 (75%) |
| Beta blocker | 10 (45%) | 8 (33%) |
| Others | 9 (39%) | 4 (17%) |
| Underlying renal disease | ||
| Glomerulopathy | 7 (30%) | 5 (21%) |
| Vascular nephropathy | 7 (30%) | 4 (17%) |
| Diabetic nephropathy | 6 (26%) | 6 (25%) |
| Others | 3 (13%) | 9 (38%) |
| Comorbidities | ||
| Arterial hypertension | 22 (96%) | 23 (96%) |
| Diabetes | 7 (30%) | 9 (38 %) |
| Cardiovascular disease | 3 (13%) | 4 (17%) |
| Congestive heart failure | 3 (13%) | 1 (4%) |
| Peripheral occlusive disease | 4 (17%) | 3 (13%) |
| COPD/Asthma | 4 (17%) | 0 |
BMI, body mass index; eGFR, estimated glomerular filtration rate; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease.